NY-PRICE-F(X)
19.12.2018 12:02:10 CET | Business Wire | Press release
Price f(x) , the global leader in cloud pricing software, has raised €25 million in Series B funding. Leading the round are Digital+ Partners, a leading European B2B technology growth investor, and Bain & Company, one of the world's top management consulting firms. The Series A investors, Prague-based Credo Ventures and London-based Talis Capital, also participated in the round.
Established in 2011 in Munich, Price f(x) provides a modular SaaS solution for Price Optimization, Management (PO&M) and Configure-Price-Quote (CPQ) for enterprises of any size, based on the latest in native cloud architecture. The company currently serves over 80 global, blue-chip B2B and B2C customers across a variety of industries, including Robert Bosch, SchneiderElectric, Owens-Illinois, Iron Mountain and Sonoco. Price f(x) has also developed a strong partner ecosystem with leading global technology, consulting and integration providers—including Bain & Company and SAP—enabling a best-in-class service offering, which helps customers realize a fast time-to-value on their pricing projects.
“Price f(x) has become the leading SaaS pricing solution provider on the market through its customer centric approach and by offering a feature-rich, highly flexible pricing tool that is also risk free and fast to implement,” said Marcin Cichon, CEO and co-Founder of Price f(x). “Our success is based on the continued satisfaction and loyalty of our customers. This new funding will allow us to help even more businesses to thrive by further expanding our existing platform capabilities and also introducing a new product offering for the SME market segment.”
“We have been very impressed by what Marcin and his team have achieved to date and see a huge growth opportunity ahead for Price f(x). They have built a world-class product, driven by a relentless customer focus, and we believe they are set to become the global market leader in pricing software. We are proud and excited to co-lead this round with Bain & Company and support Price f(x) in this next stage of growth”, said Axel Krieger, Founding Partner at Digital+ Partners.
Earlier this year, Bain & Company and Price f(x) announced a partnership to develop the Bain Pricing Navigator, offering Bain & Company clients a powerful, industry-leading software tool. The solution enables customers to continuously assess and adjust pricing based on their company’s performance by leveraging real-time dashboards, proprietary insights and templates, as well as integration with CRM and ERP systems.
“For most companies, pricing is the single most effective lever to boost earnings,” said Ron Kermisch , Bain & Company’s global pricing leader. “Yet many companies leave money on the table because they do not set the best price or ensure customers actually pay the price they have determined. Bain & Company sees investing in Price f(x) as a great opportunity to help Price f(x) to become the de-facto standard in pricing and with that to be also the best-of-breed competitive weapon for Bain’s clients, to stay at the cutting edge of pricing.”
Over the last decade, Bain & Company has developed a deep understanding of pricing strategy and a proven track record of results, working with B2B and B2C companies globally across industries. A Bain & Company survey of more than 1,700 pricing decision-makers found that 70 percent of companies believe pricing is a top management priority. However, more than half of respondents conclude that management has insufficient visibility into pricing decisions. Furthermore, fewer than 20 percent of the companies surveyed have appropriate tools and dashboards to improve pricing decisions.
Ondrej Bartos, Co-Founder & Managing Partner at Credo Ventures said, “Since investing in Price f(x) alongside Talis Capital in 2016, it’s been exciting to see the company close in on their vision to become the leader in price optimization software solutions. The energy and resilience demonstrated by Marcin and his team is what makes truly successful companies and we are grateful to be part of their journey.”
Price f(x) is a member of the Bain Alliance Ecosystem – a network of best-of-breed partnerships with complementary tool, technology, and service providers that accelerates delivery of breakthrough client results. Through the Bain Alliance Ecosystem, Bain & Company clients have access to relevant new capabilities, enabling faster assimilation of new ideas, skills, and ways of working.
###
About Price f(x)
Established in 2011 in Germany, Price f(x) AG is the provider of a full suite of price management and CPQ SaaS solution based on latest native cloud architecture, offering broad and flexible support to the entire price management closed loop cycle of Price Strategy, Controlling, Setting and Realization. The solution is suitable for B2B and B2C as well as for any industry, any size of business and geographical location. Price f(x)’s vision is to remain the leading SaaS pricing and CPQ platform provider through offering easy to use, fast to implement, flexible to adapt, risk free and inexpensive, comprehensive solutions. Price f(x)’s business model is entirely based on the satisfaction and loyalty of its customers. For more information please visit: www.pricefx.com .
About Digital+ Partners
Digital+ Partners is a leading technology growth equity investor focused on European and US technology companies with €350 million assets under management. Digital+ aims to support ambitious entrepreneurs build global technology companies, providing them with strategic advice and long-term financial support to help them define and execute their growth plans. The fund focuses exclusively on B2B technology companies and leverages a deep corporate network to help portfolio companies access new markets and build new partnerships. For more information please visit: http://www.dplus.partners .
About Bain & Company, Inc.
Bain & Company is the management consulting firm that the world's business leaders come to when they want results. Bain advises clients on strategy, operations, information technology, organization, private equity, digital transformation and strategy, and mergers and acquisition, developing practical insights that clients act on and transferring skills that make change stick. The firm aligns its incentives with clients by linking its fees to their results. Bain clients have outperformed the stock market 4 to 1. Founded in 1973, Bain has 57 offices in 36 countries, and its deep expertise and client roster cross every industry and economic sector. For more information visit: www.bain.com . Follow us on Twitter @BainAlerts .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005264/en/
Contact:
Price f(x) Marcin Cichon CEO +49 (0) 180 5-7742339 info@pricefx.eu
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom